Every 10-Q that BioNexus Gene Lab Corp (BGLC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BGLC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BGLC filings page.
BioNexus Gene Lab Corp. reported sharply lower activity for the six months ended June 30, 2026. Revenue fell to $98,998 from $4,397,328 a year earlier, almost entirely from its industrial chemicals segment, with genomic screening services contributing only $1,961. Gross profit was $12,192 and the company recorded a net loss of $830,026, improved from a loss of $1,239,499 in the prior-year period, helped by $178,691 of other income and tighter operating spending.
Total assets were $8,726,423, including cash and cash equivalents of $2,391,945 and investments in equity securities of $2,026,543. Current liabilities were $812,938, leaving positive working capital, and stockholders’ equity was $7,778,442. However, the company disclosed a substantial doubt about its ability to continue as a going concern, citing the cumulative deficit of $7,257,253, the $830,026 net loss, and $570,162 of operating cash outflows. Management believes existing cash and positive working capital can fund operations for at least twelve months, while noting it may seek additional financing that could include dilutive equity issuance or restrictive debt.
BioNexus Gene Lab Corp (BGLC) 10-Q excerpts show corporate and balance-sheet details without full financial statements. The company reports 300,000,000 shares authorized with 1,796,597 shares outstanding in one period and 1,796,766 shares outstanding at December 31, 2024 (post-reverse split basis). The company disclosed the 2017 acquisition of Bionexus Gene Lab Sdn. Bhd., later renamed MRNA Scientific Sdn. Bhd. It records trade receivables at invoiced amounts less an allowance for expected credit losses, writes off uncollectible accounts, and notes typical receivable terms range from 30 to 90 days. One customer was charged interest at 6% per annum through June 2023 and the rate increased to 8.4% from July 2023. The filing notes 1,044,351 shares issued due to a round-up and corporate governance actions at subsidiary Chemrex Corporation Sdn. Bhd., including additional directors, policy updates, and enhanced reporting to the company CFO and Audit Committee.